Pfizer (NYSE:PFE)‘s stock had its “buy” rating reaffirmed by TheStreet in a research note issued on Tuesday, Analyst Ratings News reports.
The analysts wrote, “Pfizer (PFE) has been reiterated by TheStreet Ratings as a buy with a ratings score of A. The company’s strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.”
Several other analysts have also recently commented on the stock. Analysts at Cowen and Company downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating in a research note to investors on Friday, January 10th. They now have a $34.00 price target on the stock. Separately, analysts at UBS AG downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note to investors on Thursday, January 9th. Finally, analysts at Jefferies Group raised their price target on shares of Pfizer from $31.00 to $33.00 in a research note to investors on Thursday, January 9th. They now have a “hold” rating on the stock. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have given a buy rating to the company’s stock. Pfizer currently has a consensus rating of “Hold” and an average target price of $31.78.
Pfizer (NYSE:PFE) opened at 31.28 on Tuesday. Pfizer has a 52 week low of $26.42 and a 52 week high of $32.50. The stock’s 50-day moving average is $30.82 and its 200-day moving average is $29.78. The company has a market cap of $202.7 billion and a P/E ratio of 8.58.
The company also recently declared a quarterly dividend, which is scheduled for Tuesday, March 4th. Investors of record on Friday, February 7th will be given a dividend of 0.26 per share. This represents a $1.04 dividend on an annualized basis and a yield of 3.35%. The ex-dividend date of this dividend is Wednesday, February 5th. This is an increase from Pfizer’s previous quarterly dividend of $0.24.
In other Pfizer news, EVP Frank Damelio unloaded 131,810 shares of Pfizer stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $30.82, for a total transaction of $4,062,384.20. Following the completion of the sale, the executive vice president now directly owns 356,451 shares in the company, valued at approximately $10,985,820. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.